Charles River Laboratories International, Inc. (CRL)
NYSE: CRL · Real-Time Price · USD
167.74
-17.06 (-9.23%)
Apr 23, 2026, 4:00 PM EDT - Market closed
CRL Stock Forecast
Stock Price Forecast
The 11 analysts that cover CRL stock have a consensus rating of "Buy" and an average price target of $198.27, which forecasts a 18.20% increase in the stock price over the next year. The lowest target is $160 and the highest is $265.
Price Target: $198.27 (+18.20%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CRL stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 7 | 6 | 6 | 5 | 5 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 14 | 14 | 13 | 13 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $200 → $210 | Buy | Maintains | $200 → $210 | +25.19% | Apr 14, 2026 |
| JP Morgan | JP Morgan | Hold Maintains $165 → $160 | Hold | Maintains | $165 → $160 | -4.61% | Apr 13, 2026 |
| UBS | UBS | Hold Maintains $170 → $175 | Hold | Maintains | $170 → $175 | +4.33% | Feb 25, 2026 |
| TD Cowen | TD Cowen | Strong Buy Maintains $251 → $235 | Strong Buy | Maintains | $251 → $235 | +40.10% | Feb 20, 2026 |
| Mizuho | Mizuho | Hold Maintains $215 → $175 | Hold | Maintains | $215 → $175 | +4.33% | Feb 20, 2026 |
Financial Forecast
Revenue This Year
3.97B
from 4.02B
Decreased by -1.03%
Revenue Next Year
4.10B
from 3.97B
Increased by 3.04%
EPS This Year
11.14
from -2.91
EPS Next Year
12.28
from 11.14
Increased by 10.23%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 4.3B | 4.5B | ||||||
| Avg | 4.0B | 4.1B | ||||||
| Low | 3.8B | 3.8B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 7.1% | 13.6% | ||||||
| Avg | -1.0% | 3.0% | ||||||
| Low | -6.5% | -4.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 11.76 | 13.76 | ||||||
| Avg | 11.14 | 12.28 | ||||||
| Low | 10.65 | 11.30 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 23.5% | ||||||
| Avg | - | 10.2% | ||||||
| Low | - | 1.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.